Vertex Pharmaceuticals annual ebitda
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Vertex Pharmaceuticals EBITDA Growth & History (VRTX)
Vertex Pharmaceuticals's calculated EBITDA was $4.38B for fiscal 2025.
View full Vertex Pharmaceuticals company overviewVertex Pharmaceuticals annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $4.38B | $4.41B | — |
| 2024 | 2024-12-31 | −$25.7M | −$4.04B | — |
| 2023 | 2023-12-31 | $4.01B | −$442.4M | −9.93% |
| 2022 | 2022-12-31 | $4.46B | $1.55B | +53.24% |
| 2021 | 2021-12-31 | $2.91B | −$58.1M | −1.96% |
| 2020 | 2020-12-31 | $2.97B | $1.66B | +127.37% |
| 2019 | 2019-12-31 | $1.30B | $596.8M | +84.35% |
| 2018 | 2018-12-31 | $707.6M | $522.9M | +283.22% |
| 2017 | 2017-12-31 | $184.6M | $113.3M | +158.84% |
| 2016 | 2016-12-31 | $71.3M | $475.9M | — |
| 2015 | 2015-12-31 | −$404.5M | $224.6M | — |
| 2014 | 2014-12-31 | −$629.2M | −$67.5M | — |
| 2013 | 2013-12-31 | −$561.6M | −$646.6M | — |
| 2012 | 2012-12-31 | $84.9M | −$63.9M | −42.95% |
| 2011 | 2011-12-31 | $148.9M | $814.5M | — |
| 2010 | 2010-12-31 | −$665.6M | −$81.7M | — |
| 2009 | 2009-12-31 | −$583.9M | −$153.4M | — |
| 2008 | 2008-12-31 | −$430.5M | — | — |
Vertex Pharmaceuticals quarterly ebitda
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.30B | $100.6M | +8.36% |
| Q1 2026 | 2026-03-31 | $1.19B | $515.5M | +75.98% |
| Q4 2025 | 2025-12-31 | $1.26B | $189.1M | +17.63% |
| Q3 2025 | 2025-09-30 | $1.24B | $70.7M | +6.05% |
| Q2 2025 | 2025-06-30 | $1.20B | $4.66B | — |
| Q1 2025 | 2025-03-31 | $678.5M | −$514.5M | −43.13% |
| Q4 2024 | 2024-12-31 | $1.07B | $25.0M | +2.39% |
| Q3 2024 | 2024-09-30 | $1.17B | $89.3M | +8.27% |
| Q2 2024 | 2024-06-30 | −$3.46B | −$4.53B | — |
| Q1 2024 | 2024-03-31 | $1.19B | $375.2M | +45.88% |
| Q4 2023 | 2023-12-31 | $1.05B | −$24.4M | −2.28% |
| Q3 2023 | 2023-09-30 | $1.08B | −$83.2M | −7.15% |
| Q2 2023 | 2023-06-30 | $1.07B | −$75.8M | −6.63% |
| Q1 2023 | 2023-03-31 | $817.8M | −$259.0M | −24.05% |
| Q4 2022 | 2022-12-31 | $1.07B | $160.4M | +17.60% |
| Q3 2022 | 2022-09-30 | $1.16B | $77.2M | +7.11% |
| Q2 2022 | 2022-06-30 | $1.14B | $1.15B | — |
| Q1 2022 | 2022-03-31 | $1.08B | $160.2M | +17.48% |
| Q4 2021 | 2021-12-31 | $911.5M | $136.4M | +17.59% |
| Q3 2021 | 2021-09-30 | $1.09B | $387.3M | +55.42% |
| Q2 2021 | 2021-06-30 | −$6.6M | −$751.3M | — |
| Q1 2021 | 2021-03-31 | $916.6M | $169.6M | +22.70% |
| Q4 2020 | 2020-12-31 | $775.1M | $197.5M | +34.20% |
| Q3 2020 | 2020-09-30 | $698.9M | $573.7M | +458.30% |
| Q2 2020 | 2020-06-30 | $744.7M | $447.1M | +150.20% |
| Q1 2020 | 2020-03-31 | $747.0M | $443.1M | +145.78% |
| Q4 2019 | 2019-12-31 | $577.6M | $431.1M | +294.15% |
| Q3 2019 | 2019-09-30 | $125.2M | −$99.7M | −44.33% |
| Q2 2019 | 2019-06-30 | $297.7M | $106.7M | +55.89% |
| Q1 2019 | 2019-03-31 | $303.9M | $158.7M | +109.27% |
| Q4 2018 | 2018-12-31 | $146.5M | $4.4M | +3.08% |
| Q3 2018 | 2018-09-30 | $224.8M | $535.7M | — |
| Q2 2018 | 2018-06-30 | $190.9M | $123.3M | +182.46% |
| Q1 2018 | 2018-03-31 | $145.2M | −$140.4M | −49.16% |
| Q4 2017 | 2017-12-31 | $142.2M | $87.1M | +158.06% |
| Q3 2017 | 2017-09-30 | −$310.8M | −$306.7M | — |
| Q2 2017 | 2017-06-30 | $67.6M | $49.3M | +269.06% |
| Q1 2017 | 2017-03-31 | $285.7M | $283.6M | +13602.25% |
| Q4 2016 | 2016-12-31 | $55.1M | $93.0M | — |
| Q3 2016 | 2016-09-30 | −$4.2M | $49.7M | — |
| Q2 2016 | 2016-06-30 | $18.3M | $175.4M | — |
| Q1 2016 | 2016-03-31 | $2.1M | $157.7M | — |
| Q4 2015 | 2015-12-31 | −$38.0M | $99.3M | — |
| Q3 2015 | 2015-09-30 | −$53.9M | $71.4M | — |
| Q2 2015 | 2015-06-30 | −$157.1M | $9.3M | — |
| Q1 2015 | 2015-03-31 | −$155.6M | $44.6M | — |
| Q4 2014 | 2014-12-31 | −$137.3M | −$144.6M | — |
| Q3 2014 | 2014-09-30 | −$125.2M | −$11.2M | — |
| Q2 2014 | 2014-06-30 | −$166.4M | −$129.9M | — |
| Q1 2014 | 2014-03-31 | −$200.3M | $218.2M | — |
| Q4 2013 | 2013-12-31 | $7.3M | $28.1M | — |
| Q3 2013 | 2013-09-30 | −$114.1M | −$121.6M | — |
| Q2 2013 | 2013-06-30 | −$36.5M | −$34.4M | — |
| Q1 2013 | 2013-03-31 | −$418.4M | −$518.7M | — |
| Q4 2012 | 2012-12-31 | −$20.7M | −$254.3M | — |
| Q3 2012 | 2012-09-30 | $7.5M | −$215.9M | −96.63% |
| Q2 2012 | 2012-06-30 | −$2.1M | $155.1M | — |
| Q1 2012 | 2012-03-31 | $100.2M | $251.3M | — |
| Q4 2011 | 2011-12-31 | $233.6M | $392.1M | — |
| Q3 2011 | 2011-09-30 | $223.5M | $416.3M | — |
| Q2 2011 | 2011-06-30 | −$157.2M | $4.5M | — |
| Q1 2011 | 2011-03-31 | −$151.0M | $1.7M | — |
| Q4 2010 | 2010-12-31 | −$158.4M | −$20.1M | — |
| Q3 2010 | 2010-09-30 | −$192.8M | −$51.4M | — |
| Q2 2010 | 2010-06-30 | −$161.7M | −$12.2M | — |
| Q1 2010 | 2010-03-31 | −$152.7M | $2.0M | — |
| Q4 2009 | 2009-12-31 | −$138.3M | — | — |
| Q3 2009 | 2009-09-30 | −$141.4M | — | — |
| Q2 2009 | 2009-06-30 | −$149.4M | — | — |
| Q1 2009 | 2009-03-31 | −$154.7M | — | — |
Vertex Pharmaceuticals ebitda trends
Over the last five fiscal years, Vertex Pharmaceuticals's ebitda increased from $2.97B to $4.38B, a change of $1.42B. The latest reported quarter, Q2 2026, shows $1.30B.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vertex Pharmaceuticals source filings ↗